Spero Therapeutics, Inc.
SPRONASDAQHealthcare● Active
$2.74
$-0.08(-2.84%)
Market Cap$158650091
P/E Ratio—
52W High$3.22
52W Low$1.8
Spero Therapeutics, Inc. (SPRO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SPRO · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.13
Est. -$0.18 · +27.8%
Revenue
$0.00B
Est. $0.00B · +0.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▲ Beat EPS🔥 5-Quarter EPS Beat Streak
SPRO reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.17 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 13, 2026 | -$0.18 | -$0.13 | +27.8% | $0.00B | $0.00B | +0.0% |
| ▲ Q1 FY2026 | Mar 26, 2026 | -$0.20 | $0.53 | +365.0% | $0.04B | $0.03B | +58.8% |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$0.25 | -$0.13 | +48.0% | $0.00B | $0.01B | -74.6% |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$0.38 | -$0.03 | +92.1% | $0.01B | $0.01B | +7.3% |
| ▲ Q2 FY2025 | May 13, 2025 | -$0.55 | -$0.25 | +54.5% | $0.01B | $0.01B | -46.6% |
| ▼ Q1 FY2025 | Mar 27, 2025 | -$0.35 | -$0.38 | -8.6% | $0.01B | $0.01B | +50.9% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$0.27 | -$0.32 | -18.5% | $0.01B | $0.00B | +225.9% |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.17
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Beat
EPS Actual
-$0.13
EPS Est.
-$0.18
EPS Surpr.
+27.8%
Revenue
$0.00B
Q1 FY2026
Mar 26, 2026Beat
EPS Actual
$0.53
EPS Est.
-$0.20
EPS Surpr.
+365.0%
Revenue
$0.04B
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$0.13
EPS Est.
-$0.25
EPS Surpr.
+48.0%
Revenue
$0.00B
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
-$0.03
EPS Est.
-$0.38
EPS Surpr.
+92.1%
Revenue
$0.01B
Q2 FY2025
May 13, 2025Beat
EPS Actual
-$0.25
EPS Est.
-$0.55
EPS Surpr.
+54.5%
Revenue
$0.01B
Q1 FY2025
Mar 27, 2025Miss
EPS Actual
-$0.38
EPS Est.
-$0.35
EPS Surpr.
-8.6%
Revenue
$0.01B
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$0.32
EPS Est.
-$0.27
EPS Surpr.
-18.5%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.14 | $-0.14 | $-0.14 | 1 |
| Q3 FY2026 | $-0.16 | $-0.16 | $-0.16 | 1 |
| Q2 FY2026 | $-0.17 | $-0.17 | $-0.17 | 1 |
| Q1 FY2026 | $-0.18 | $-0.18 | $-0.18 | 1 |
| Q4 FY2025 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Q3 FY2025 | $-0.25 | $-0.25 | $-0.25 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 13, 2026 | +27.8% | $2.54 | $2.44 | -3.94% |
| ▲ Q1 FY2026 | Mar 26, 2026 | +365.0% | $2.41 | $2.37 | -1.66% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +48.0% | $2.66 | $2.44 | -8.27% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +92.1% | $2.20 | $2.36 | +7.27% |
| ▲ Q2 FY2025 | May 13, 2025 | +54.5% | $0.61 | $0.69 | +13.11% |
| ▼ Q1 FY2025 | Mar 27, 2025 | -8.6% | $0.89 | $0.86 | -3.36% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -18.5% | $1.31 | $1.25 | -4.58% |
| ▲ Q3 FY2024 | Aug 5, 2024 | +5.7% | $1.31 | $1.34 | +2.29% |
Q2 FY2026-3.94%
Report Date
May 13, 2026
EPS Beat/Miss
+27.8%
Price Before
$2.54
Price After
$2.44
Q1 FY2026-1.66%
Report Date
Mar 26, 2026
EPS Beat/Miss
+365.0%
Price Before
$2.41
Price After
$2.37
Q4 FY2025-8.27%
Report Date
Nov 13, 2025
EPS Beat/Miss
+48.0%
Price Before
$2.66
Price After
$2.44
Q3 FY2025+7.27%
Report Date
Aug 12, 2025
EPS Beat/Miss
+92.1%
Price Before
$2.20
Price After
$2.36
Q2 FY2025+13.11%
Report Date
May 13, 2025
EPS Beat/Miss
+54.5%
Price Before
$0.61
Price After
$0.69
Q1 FY2025-3.36%
Report Date
Mar 27, 2025
EPS Beat/Miss
-8.6%
Price Before
$0.89
Price After
$0.86
Q4 FY2024-4.58%
Report Date
Nov 14, 2024
EPS Beat/Miss
-18.5%
Price Before
$1.31
Price After
$1.25
Q3 FY2024+2.29%
Report Date
Aug 5, 2024
EPS Beat/Miss
+5.7%
Price Before
$1.31
Price After
$1.34
Avg Beat Reaction+1.47%
Avg Miss Reaction-3.97%
Beat Rate6 / 8 quarters
Largest Move+13.11% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SPRO ends December
Spero Therapeutics, Inc. (SPRO) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.13 — beating the analyst consensus of $-0.18 by +27.8%. SPRO has beaten EPS estimates for 5 consecutive quarters. The next SPRO earnings date is expected around September 1, 2026.
Each quarter, investors track SPRO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SPRO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SPRO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SPRO earnings · 5 questionsSpero Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. SPRO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SPRO historically reports after market close (AMC).
SPRO earnings datewhen is SPRO earningsSPRO next earnings datewhen does SPRO report earningsSPRO earnings calendar
▸ Source: FMP · Spero Therapeutics, Inc. SEC filings · US GAAP · Spero Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026